Adaptimmune Therapeutics plc (NASDAQ: ADAP) stock closed at 0.7825 per share at the end of the most recent trading day (a 1.9% change compared to the prior day closing price) with a volume of 252.54K shares and market capitalization of 176.98M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 462 people. Adaptimmune Therapeutics plc CEO is Adrian Rawcliffe.

The one-year performance of Adaptimmune Therapeutics plc stock is -42.26%, while year-to-date (YTD) performance is -46.4%. ADAP stock has a five-year performance of -93.32%. Its 52-week range is between 0.6801 and 2.65, which gives ADAP stock a 52-week price range ratio of 5.20%

Adaptimmune Therapeutics plc currently has a PE ratio of -2.00, a price-to-book (PB) ratio of 3.12, a price-to-sale (PS) ratio of 19.77, a price to cashflow ratio of 127.40, a PEG ratio of -, a ROA of -55.43%, a ROC of -87.30% and a ROE of -110.28%. The company’s profit margin is -%, its EBITDA margin is -984.90%, and its revenue ttm is $16.12 Million , which makes it $0.10 revenue per share.

Of the last four earnings reports from Adaptimmune Therapeutics plc, there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.20 for the next earnings report. Adaptimmune Therapeutics plc’s next earnings report date is 14th Nov 2023.

The consensus rating of Wall Street analysts for Adaptimmune Therapeutics plc is Moderate Buy (2.14), with a target price of $6.67, which is +752.40% compared to the current price. The earnings rating for Adaptimmune Therapeutics plc stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Adaptimmune Therapeutics plc has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Adaptimmune Therapeutics plc has a Neutral technical analysis rating based on Technical Indicators (ADX : 16.82, ATR14 : 0.05, CCI20 : -15.78, Chaikin Money Flow : 0.01, MACD : -0.02, Money Flow Index : 37.63, ROC : 2.96, RSI : 48.52, STOCH (14,3) : 60.27, STOCH RSI : 0.79, UO : 59.77, Williams %R : -39.73), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Adaptimmune Therapeutics plc in the last 12-months were: Adrian Rawcliffe (Sold 46 935 shares of value $82 071 ), Cintia Piccina (Sold 11 890 shares of value $22 230 ), Elliot Norry (Sold 14 327 shares of value $24 916 ), John Lunger (Sold 14 356 shares of value $25 310 ), Lunger John (Sold 14 356 shares of value $25 346 ), Norry Elliot (Sold 14 327 shares of value $24 959 ), Piccina Cintia (Sold 11 890 shares of value $22 234 ), Rawcliffe Adrian (Sold 51 671 shares of value $86 208 ), William C. Bertrand (Sold 16 840 shares of value $29 518 )